^
    Back
    Association details:
    Biomarker:MYC expression + PAICS expression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

    Published date:
    11/06/2019
    Excerpt:
    Through the nCounter-based transcriptome profiling of formalin-fixed paraffin-embedded (FFPE) tissues from 170 untreated DLBCL patients, we found that MYC and PAICS were co-expressed and their mRNA levels were among the most predictive for poor prognosis after standard R-CHOP therapy.
    DOI:
    https://doi.org/10.1182/blood-2019-129613